
Colombia Opens First Medical Cannabis Pharmacy in Medellín
Green Marketplace introduces prescription-based dispensing with full traceability system
Green Marketplace Pharmacy has opened its doors in Medellín, marking a milestone as Colombia's first specialized medical cannabis pharmacy. The facility operates under a prescription-based model with full product traceability—a system that could set the standard for the country's emerging medical cannabis retail sector.
The pharmacy represents a significant step forward for Colombia's medical cannabis program, which has been building regulatory infrastructure since legalizing medical cannabis in 2016. While the country has become a major exporter of cannabis products, particularly to markets in Europe and North America, domestic retail infrastructure has lagged behind cultivation and manufacturing.
Green Marketplace's prescription requirement aligns with Colombia's medical cannabis framework, which mandates physician authorization for patient access. The traceability system tracks products from licensed cultivators through the supply chain to end users—a level of oversight that mirrors seed-to-sale tracking requirements in established markets like Canada and several U.S. states.
Why Colombia Matters
Colombia has emerged as one of Latin America's most ambitious cannabis markets over the past seven years. The country's equatorial climate, low production costs, and existing agricultural expertise have attracted significant foreign investment from Canadian and U.S. cannabis companies. Firms like Aurora Cannabis and Clever Leaves have established major cultivation operations in the country.
But while Colombia has issued hundreds of cultivation licenses and exports millions of dollars in cannabis products annually, the domestic medical market has developed more slowly. Regulatory complexity and limited retail infrastructure have constrained patient access, even as the country ships cannabis flower and extracts worldwide.
The opening of a specialized pharmacy in Medellín—Colombia's second-largest city—signals that domestic market development may be accelerating. The city's population of 2.5 million represents a substantial patient base for medical cannabis products.
What's Next
The success of Green Marketplace could influence how other Colombian cities approach medical cannabis retail. Several regions have expressed interest in developing similar pharmacy models, though regulatory approval processes vary by municipality.
Colombia's medical cannabis market faces competition from other Latin American countries moving forward with their own programs. Mexico, Argentina, and Brazil have all advanced medical cannabis legislation in recent years, though implementation timelines differ significantly.
For international cannabis companies already operating cultivation facilities in Colombia, a functioning domestic retail market could provide an additional revenue stream beyond export sales. The country's relatively affordable pricing compared to North American markets may also make it an attractive destination for medical cannabis tourism, though current regulations focus primarily on resident patient access.
Industry observers will be watching whether Green Marketplace's model proves scalable across Colombia's major urban centers, and whether the traceability system helps address concerns about product diversion that have complicated cannabis programs in other markets.
This article is based on original reporting by hightimes.com.
Original Source
This article is based on reporting from High Times.
Read the original articleOriginal title: "Colombia’s First Specialized Medical Cannabis Pharmacy Opens In Medellín: Inside Green Marketplace"
Related Topics
Related Stories
InternationalSpain's Cannabis Concentrate Market Shifts From BHO to Rosin
Spanish cannabis extractors are abandoning dangerous butane methods for solventless rosin production as police raids increase, creating a volatile market caught between safety concerns and legal uncertainty.
InternationalSwitzerland Extends Zurich Cannabis Pilot to 2028 After Strong Results
Switzerland extended Zurich's legal cannabis pilot to 2028 after data showed 67% reduction in black market purchases and improved public health outcomes among 2,100 registered participants.
Medical CannabisSurvey of 3,500 Patients Shows Medical Cannabis Reduces Prescription Drug Use
A survey of over 3,500 medical cannabis patients found reduced use of opioids, sleep aids, and antidepressants after starting cannabis treatment, with fewer reported side effects than prescription medications.
More from Alex Morgan
View all articles
Trump's Psychedelics Research Order Draws Bipartisan Praise

Massachusetts Doubles Cannabis Possession Limit to 4 Ounces

Automation Gap Leaves Cannabis Brands Struggling to Scale Operations

